# ACELYRIN INC. (SLRN) Source: https://www.quantisnow.com/company/SLRN Generated: 2026-11-09T12:53:08.248Z - Ticker: SLRN - Exchange: NASDAQ - Sector: Health Care - Industry: Biotechnology: Pharmaceutical Preparations - IPO year: 2023 ## Latest SLRN news and filings - 2025-05-23 20:23 UTC [SEC Form 4] [Director Ayurmaya Capital Management Company, Lp returned 9,334,735 shares to the company (SEC Form 4)](https://www.quantisnow.com/insight/director-ayurmaya-capital-management-company-lp-returned-9334735-shares-to-6056920) - 2025-05-23 20:15 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by ACELYRIN INC.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-acelyrin-inc-6056796) - 2025-05-23 20:11 UTC [SEC Form 4] [Chief Executive Officer Kim Mina was granted 89,526 shares and returned 770,833 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-kim-mina-was-granted-89526-shares-and-6056696) - 2025-05-23 20:11 UTC [SEC Form 4] [SEC Form 4 filed by Director Cozadd Bruce C](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-cozadd-bruce-c-6056690) - 2025-05-23 20:10 UTC [SEC Form 4] [Chief Legal Officer Murugan Amar returned 121,587 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-legal-officer-murugan-amar-returned-121587-shares-to-the-6056679) - 2025-05-23 20:09 UTC [SEC Form 4] [Director Seidenberg Beth C returned 9,850,729 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-seidenberg-beth-c-returned-9850729-shares-to-the-company-6056643) - 2025-05-23 20:08 UTC [SEC Form 4] [Chief Medical Officer Mpofu Shephard returned 121,789 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-mpofu-shephard-returned-121789-shares-to-the-6056616) - 2025-05-23 20:07 UTC [SEC Form 4] [Director Gosebruch Henry O returned 50,000 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-gosebruch-henry-o-returned-50000-shares-to-the-company-6056597) - 2025-05-23 20:06 UTC [SEC Form 4] [Director Machado Patrick returned 14,675 shares to the company (SEC Form 4)](https://www.quantisnow.com/insight/director-machado-patrick-returned-14675-shares-to-the-company-sec-6056584) - 2025-05-23 20:06 UTC [SEC Form 4] [Director Svoronos Dawn returned 15,000 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-svoronos-dawn-returned-15000-shares-to-the-company-closing-6056549) - 2025-05-23 20:05 UTC [SEC Form 4] [Director Becker Daniel J. returned 2,999 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-becker-daniel-j-returned-2999-shares-to-the-company-6056513) - 2025-05-23 20:04 UTC [SEC Form 4] [SEC Form 4 filed by Director Tetrault Lynn A.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-tetrault-lynn-a-6056453) - 2025-05-23 20:01 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by ACELYRIN INC.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-acelyrin-inc-6056397) - 2025-05-23 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by ACELYRIN INC.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-acelyrin-inc-6055729) - 2025-05-21 23:20 UTC [SEC Form POS AM filed by ACELYRIN INC.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-acelyrin-inc-6053331) - 2025-05-21 23:25 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by ACELYRIN INC.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-acelyrin-inc-6053326) - 2025-05-21 23:26 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by ACELYRIN INC.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-acelyrin-inc-6053325) - 2025-05-21 23:27 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by ACELYRIN INC.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-acelyrin-inc-6053324) - 2025-05-21 17:51 UTC [SEC Form 25-NSE filed by ACELYRIN INC.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-acelyrin-inc-6052107) - 2025-05-21 13:24 UTC [SEC Form 8-K] [ACELYRIN INC. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Completion of Acquisition or Disposition of Assets](https://www.quantisnow.com/insight/acelyrin-inc-filed-sec-form-8-k-notice-of-delisting-or-6051911) - 2025-05-19 20:46 UTC [SEC Form 4] [Chief Executive Officer Kim Mina was granted 30,851 shares and covered exercise/tax liability with 21,297 shares, increasing direct ownership by 1% to 681,307 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-kim-mina-was-granted-30851-shares-and-6048262) - 2025-05-19 20:20 UTC [SEC Form 8-K] [SEC Form 8-K filed by ACELYRIN INC.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-acelyrin-inc-6047914) - 2025-05-14 20:03 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by ACELYRIN INC.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-acelyrin-inc-6038659) - 2025-05-13 17:00 UTC [Alumis Stockholders Approve Merger with ACELYRIN](https://www.quantisnow.com/insight/alumis-stockholders-approve-merger-with-acelyrin-6035475) - 2025-05-13 17:00 UTC [ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases](https://www.quantisnow.com/insight/acelyrin-stockholders-approve-merger-with-alumis-to-create-clinical-biopharma-6035474) - 2025-05-06 21:16 UTC [SEC Form 425] [SEC Form 425 filed by ACELYRIN INC.](https://www.quantisnow.com/insight/sec-form-425-filed-by-acelyrin-inc-6021876) - 2025-05-06 21:14 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by ACELYRIN INC.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-acelyrin-inc-6021867) - 2025-05-06 20:30 UTC [Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote "FOR" the Proposed Transaction with Alumis](https://www.quantisnow.com/insight/leading-independent-proxy-advisory-firm-iss-recommends-acelyrin-stockholders-vote-6021380) - 2025-05-01 18:46 UTC [SEC Form 425] [SEC Form 425 filed by ACELYRIN INC.](https://www.quantisnow.com/insight/sec-form-425-filed-by-acelyrin-inc-6012960) - 2025-05-01 17:30 UTC [ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis](https://www.quantisnow.com/insight/acelyrin-reiterates-benefits-of-value-maximizing-combination-with-alumis-6012883) - 2025-05-01 00:27 UTC [SEC Form SCHEDULE 13D filed by ACELYRIN INC.](https://www.quantisnow.com/insight/sec-form-schedule-13d-filed-by-acelyrin-inc-6011522) - 2025-04-29 13:09 UTC [SEC Form 425] [SEC Form 425 filed by ACELYRIN INC.](https://www.quantisnow.com/insight/sec-form-425-filed-by-acelyrin-inc-6006452) - 2025-04-23 21:09 UTC [SEC Form DEFR14A filed by ACELYRIN INC.](https://www.quantisnow.com/insight/sec-form-defr14a-filed-by-acelyrin-inc-5998775) - 2025-04-21 20:23 UTC [SEC Form 425] [SEC Form 425 filed by ACELYRIN INC.](https://www.quantisnow.com/insight/sec-form-425-filed-by-acelyrin-inc-5994805) - 2025-04-21 11:41 UTC [SEC Form 425] [SEC Form 425 filed by ACELYRIN INC.](https://www.quantisnow.com/insight/sec-form-425-filed-by-acelyrin-inc-5994066) - 2025-04-21 10:32 UTC [SEC Form 425] [SEC Form 425 filed by ACELYRIN INC.](https://www.quantisnow.com/insight/sec-form-425-filed-by-acelyrin-inc-5993985) - 2025-04-21 10:31 UTC [SEC Form 425] [SEC Form 425 filed by ACELYRIN INC.](https://www.quantisnow.com/insight/sec-form-425-filed-by-acelyrin-inc-5993984) - 2025-04-21 10:30 UTC [SEC Form 8-K] [ACELYRIN INC. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure](https://www.quantisnow.com/insight/acelyrin-inc-filed-sec-form-8-k-entry-into-a-material-5993983) - 2025-04-21 10:30 UTC [Alumis and ACELYRIN Announce Amended Merger Agreement](https://www.quantisnow.com/insight/alumis-and-acelyrin-announce-amended-merger-agreement-5993978) - 2025-04-04 20:41 UTC [SEC Form 425] [SEC Form 425 filed by ACELYRIN INC.](https://www.quantisnow.com/insight/sec-form-425-filed-by-acelyrin-inc-5978224) ## More - Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/SLRN - Earnings history: https://www.quantisnow.com/earnings/SLRN - Dividend history: https://www.quantisnow.com/dividends/SLRN - Insider transactions: https://www.quantisnow.com/insiders/SLRN - Options chain: https://www.quantisnow.com/options/SLRN - SEC 8-K filings only: https://www.quantisnow.com/company/SLRN/8-k - RSS and alerts for SLRN: https://www.quantisnow.com/docs/rss-feeds.md